Guided Therapeutics (GTHP) Equity Ratio (2010 - 2025)

Guided Therapeutics has disclosed Equity Ratio across 16 years of filings, most recently posting 4.53 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 4.53, down 27.73% year-over-year; the trailing twelve-month figure through Dec 2025 was 4.53 (down 27.73% YoY), and the FY2025 annual result was 4.53, down 27.73% from the prior year.
• Equity Ratio came in at 4.53 for Q4 2025 at Guided Therapeutics, up from 6.31 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.68 in Q3 2022 to a low of 6.31 in Q3 2025.
• The 5-year median for Equity Ratio is 3.47 (2021), against an average of 3.22.
• Across the five-year window, Equity Ratio soared 89.14% in 2021 and plunged 183.95% in 2023, its largest moves.
• Guided Therapeutics' Equity Ratio stood at 2.67 in 2021, then soared by 67.91% to 0.86 in 2022, then slumped by 166.25% to 2.28 in 2023, then plunged by 55.58% to 3.55 in 2024, then dropped by 27.73% to 4.53 in 2025.
• The last three Equity Ratio figures came in at 4.53 (Q4 2025), 6.31 (Q3 2025), and 5.82 (Q2 2025), per Business Quant data.